Abstract:Circulation Research, Ahead of Print. BACKGROUND:Cardiac hypertrophy is an adaptive response to pressure overload aimed at maintaining cardiac function. However, prolonged hypertrophy significantly increases the risk of maladaptive cardiac remodeling and heart failure. Recent studies have implicated long noncoding RNAs in cardiac hypertrophy and cardiomyopathy, but their significance and mechanism(s) of action are not well understood.METHODS:We measuredlincRNA-p21RNA and H3K27ac levels in the hearts of dilated cardiomyopathy patients. We assessed the functional role oflincRNA-p21in basal and surgical pressure-overload conditions using loss-of-function mice. Genome-wide transcriptome analysis revealed dysregulated genes and pathways. We labeled proteins in proximity to full-lengthlincRNA-p21using a novel BioID2-based system. We immunoprecipitatedlincRNA-p21-interacting proteins and performed cell fractionation, ChIP-seq (chromatin immunoprecipitation followed by sequencing), and co-immunoprecipitation to investigate molecular interactions and underlying mechanisms. We used GapmeR antisense oligonucleotides to evaluate the therapeutic potential oflincRNA-p21inhibition in cardiac hypertrophy and associated heart failure.RESULTS:lincRNA-p21was induced in mice and humans with cardiomyopathy. Global and cardiac-specificlincRNA-p21knockout significantly suppressed pressure overload-induced ventricular wall thickening, stress marker elevation, and deterioration of cardiac function. Genome-wide transcriptome analysis and transcriptional network analysis revealed thatlincRNA-p21actsin transto stimulate the NFAT/MEF2 pathway. Mechanistically,lincRNA-p21is bound to the scaffold protein KAP1.lincRNA-p21cardiac-specific knockout suppressed stress-induced nuclear accumulation of KAP1, and KAP1 knockdown attenuated cardiac hypertrophy and NFAT activation. KAP1 positively regulates pathological hypertrophy by physically interacting with NFATC4 to promote the overactive status of NFAT/MEF2 signaling. GapmeR antisense oligonucleotide depletion oflincRNA-p21similarly inhibited cardiac hypertrophy and adverse remodeling, highlighting the therapeutic potential of inhibitinglincRNA-p21.CONCLUSIONS:These findings advance our understanding of the functional significance of stress-induced long noncoding RNA in cardiac hypertrophy and demonstrate the potential oflincRNA-p21as a novel therapeutic target for cardiac hypertrophy and subsequent heart failure.

Therapeutic Inhibition of LincRNA-p21 Protects Against Cardiac Hypertrophy

Inhibition of TRPC1 Prevents Cardiac Hypertrophy Via NF-κB Signaling Pathway in Human Pluripotent Stem Cell-Derived Cardiomyocytes.

Lincrna-P21 Regulates Neointima Formation, Vascular Smooth Muscle Cell Proliferation, Apoptosis, and Atherosclerosis by Enhancing P53 Activity

Inhibition of long noncoding RNA Gm41724 alleviates pressure overload-induced cardiac fibrosis by regulating lamina-associated polypeptide 2α

LincRNA-p21 Upregulates Nuclear Orphan Receptor Nr4a2 and Aggravates Myocardial Ischemia/Reperfusion Injury via Targeting MiR-466i-5p

LncRNA LncHrt preserves cardiac metabolic homeostasis and heart function by modulating the LKB1-AMPK signaling pathway

Targeting muscle-enriched long non-coding RNA H19 reverses pathological cardiac hypertrophy

Identification of a long noncoding RNA Gm17501 as a novel negative regulator of cardiac hypertrophy

The Long Noncoding RNA CARDINAL Attenuates Cardiac Translation

Silencing N29 Regulated miR‐193b‐5p/TGFBR2 Axis to Mitigate the Progression of Cardiac Hypertrophy

Abstract 91: Genome-wide Identification and Characterization of Cardiac Hypertrophy-related Long Noncoding RNAs in Mice

The function of LncRNA-H19 in cardiac hypertrophy

lncRNA Gm20257 alleviates pathological cardiac hypertrophy by modulating the PGC-1α-mitochondrial complex IV axis

The Lncrna Plscr4 Controls Cardiac Hypertrophy by Regulating Mir-214

LncRNAs in Cardiac Hypertrophy: from Basic Science to Clinical Application

LTBP2 Knockdown Ameliorates Cardiac Fibrosis and Apoptosis via Attenuating NF‐κB Signaling Pathway and Oxidative Stress in Mice with Cardiac Hypertrophy

lncExACT1 and DCHS2 Regulate Physiological and Pathological Cardiac Growth

HIPK1 Inhibition Protects against Pathological Cardiac Hypertrophy by Inhibiting the CREB‐C/EBPβ Axis

The Long Noncoding RNA Chaer Defines an Epigenetic Checkpoint in Cardiac Hypertrophy

HIPK1 Inhibition Protects Against Pathological Cardiac Hypertrophy by Inhibiting the CREB-C/EBP Axis

Long Non-Coding RNAs in Cardiac Remodeling